Raoul S. Concepcion, MD, FACS, presented “New Considerations for Oligometastatic Prostate Cancer” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.
How to cite: Concepcion, Raoul S. “New Considerations for Oligometastatic Prostate Cancer” January 26, 2019. Accessed Nov 2024. https://dev.grandroundsinurology.com/new-considerations-for-oligometastatic-prostate-cancer-2/
New Considerations for Oligometastatic Prostate Cancer – Summary:
Raoul S. Concepcion, MD, FACS, discusses the management of patients with oligometastatic prostate cancer. Currently, there is no standard definition of what defines oligometastatic. Additionally, questions remain about the handling of the primary tumor in this setting, as well as whether therapy directed at the primary has a long term benefit in overall survival. Also, physicians must take into consideration patients presenting with synchronous or metachronous lesions, the location of their disease (bone, nodal or visceral), and whether or not they are hormone-naïve versus castration-resistant. Increasing utilization of biomolecular/next generation imaging will surely compound the issue, due to the increased sensitivity of these scans relative to traditional staging modalities. In this presentation, Dr. Concepcion highlights these issues and reviews the current status of this challenging, evolving patient population.
About the International Prostate Cancer Update
The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Concepcion presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.
ABOUT THE AUTHOR
Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there.
Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, he founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.
